Urogen Pharma Ltd (OQ:URGN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 9 Ha'ta'asiya St
RA'ANANA 4365007
Tel: N/A
Website: N/A
IR: N/A
<
Key People
Arie S. Belldegrun
Independent Chairman of the Board
Elyse G. Seltzer
Chief Development Officer
Elizabeth A. Barrett
President, Chief Executive Officer, Director
Molly Henderson
Chief Financial Officer, Principal Accounting Officer
Marina Konorty
Executive Vice President, Research & Development and Technical Operations
Jim Ottinger
Executive Vice President, Regulatory Affairs and Quality
Jason Drew Smith
Chief Compliance Officer, General Counsel
Jeff Bova
Chief Commercial Officer
Polly A Murphy
Chief Business Officer
Mark P. Schoenberg
Chief Medical Officer
   
Business Overview
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Financial Overview
For the nine months ended 30 September 2020, UrogenPharma Ltd revenues increased from $18K to $3.8M. Net lossincreased 48% to $98M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and Administrative Expenses - Ba increase from$24.9M to $51.6M (expense), Research and DevelopmentExpenses, Net increase of 31% to $29.9M (expense).
Employees: 187 as of Sep 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $321.80M as of Sep 30, 2020
Annual revenue (TTM): $3.83M as of Sep 30, 2020
EBITDA (TTM): -$138.90M as of Sep 30, 2020
Net annual income (TTM): -$136.93M as of Sep 30, 2020
Free cash flow (TTM): -$111.88M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 22,093,054 as of Nov 4, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.